1Harenberg J. Fixed dose versus adjusted dose low molecular weigh the parin for the initial treatment of patients with deep venous, thrombosis [J].Curr Opin Pulm Med, 2002, 8(5):383.
2Lensing AW, Buller HR, Prandoni P, et al. Contrast venography, the gold standard for the diagnosis deepveinthrombosis: improvement in observer agreement [J].Thromb Haemost, 19 9 2,6 7 ( 1 ) : 8-12.
3Bertina RM,Koeleman BPC, Koster T,et al. Mutation in blood coagulation factor vassociated with resistance to activated protein C[J].Nature, 1994,369 (6475) : 64-67.
4Lee CH, Hankey GJ, Ho WK, et al. Venous thromboembolism: diagnosis and management of deep venous thrombosis[J]. Med J Aust, 2005,182 (9) : 476- 481.
5Hoek JA, Nurmohamed MT, Hamelynck KJ , et al. Prevention of deep vein thrombosis following total hip replace ment by low molecular weight heparinoid [J]. Thromb Haemost, 1992,67 : 28-32.
6Hull R, Raskob G, Pineo G, et al. A comparison of subcutaneous low molecular weight heparin with warfarin sodium for prophy laxisagainst deep vein thrombosis after hip or knee implantation[J].N Engl J Med,1993, 329( 19 ):1370-1376.
7Turpie AG, Levine MN, Hirsh J, et al. Arandomized controlled trial of a low molecular weigh the parin (enoxaparin) to prevent deep vein thrombosis in patients under going elective hip surgery[J]. N Engl J Med,1986, 315( 15 ):925-929.
8Levine MN, Gent M, Hirsh J,et al. Ardeparin (low molecular weigh theparin) vsgraduatedcom pression stockings for the prevention of venous thromboembolisma ranomized trialinp atientsunder going knee surgery[J].Arch Intern Med, 1996,156( 8 ) :851-856.
